Vertex Pharmaceuticals has been granted a patent for a feeder-free cell culture method for primate pluripotent stem cells. The method involves using a defined medium with human serum in an uncoated tissue culture vessel. This innovation aims to improve the culture and maintenance of stem cells. GlobalData’s report on Vertex Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Vertex Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Vertex Pharmaceuticals's grant share as of February 2024 was 68%. Grant share is based on the ratio of number of grants to total number of patents.
Feeder-free culture of primate pluripotent stem cells
A recently granted patent (Publication Number: US11920154B2) discloses an innovative feeder-free cell culture system for primate pluripotent stem cells. The culture comprises dissociated primate pluripotent stem cells in a defined medium supplemented with 0.5% to 40% human serum, all contained within an uncoated and matrix-free tissue culture vessel. This novel approach eliminates the need for traditional feeder cells and provides a more streamlined and efficient method for culturing primate pluripotent stem cells.
Furthermore, the patent claims specify various aspects of the cell culture system, including the use of human pluripotent stem cells, particularly human embryonic stem cells, in the defined medium supplemented with human serum. The defined medium is free of non-human animal products, and the dissociated primate pluripotent stem cells are maintained in a single cell suspension within the vessel. Additionally, the defined medium supports the proliferation of the primate pluripotent stem cells in an undifferentiated state, highlighting the potential for this system to be utilized in various research and therapeutic applications.
To know more about GlobalData’s detailed insights on Vertex Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
